TY - JOUR
T1 - Cancer patients acceptance, understanding, and willingness-to-pay for pharmacogenomic testing
AU - Cuffe, Sinead
AU - Hon, Henrique
AU - Qiu, Xin
AU - Tobros, Kimberly
AU - Wong, Chung Kwun Amy
AU - De Souza, Bradley
AU - McFarlane, Graham
AU - Masroor, Sohaib
AU - Azad, Abul K.
AU - Hasani, Ekta
AU - Rozanec, Natalie
AU - Leighl, Natasha
AU - Alibhai, Shabbir
AU - Xu, Wei
AU - Issa, Amalia M.
AU - Liu, Geoffrey
PY - 2014/7
Y1 - 2014/7
N2 - BACKGROUND: Pharmacogenomics is gaining increasing importance in the therapeutics of cancer; yet, there is little knowledge of cancer patients' attitudes toward the use of pharmacogenomic testing in clinical practice. We carried out this study to explore cancer patients' acceptance, understanding, and willingness-to-pay for pharmacogenomic testing. MATERIALS AND METHODS: A broad cross-section of gastrointestinal, lung, breast, and other cancer patients were interviewed in terms of their acceptance of pharmacogenomic testing using hypothetical time, efficacy, and toxicity trade-off and willingness-to-pay scenarios. RESULTS: Among the 96% of 123 adjuvant patients accepting chemotherapy under optimal conditions, 99% wanted pharmacogenomic testing that could identify a subset of patients benefiting from chemotherapy, accepting median incurred costs of $2000 (range $0-25000) and turnaround time for test results of 16 days (range 0-90 days). Among the 97% of 121 metastatic patients accepting chemotherapy, 97.4% wanted pharmacogenomic testing that could detect the risk of severe toxicity, accepting median incurred costs of $1000 (range $0-10000) and turnaround time for results of 14 days (range 1-90 days). The majority of patients wanted to be involved in decision-making on pharmacogenomic testing; however, one in five patients lacked a basic understanding of pharmacogenomic testing. CONCLUSION: Among cancer patients willing to undergo chemotherapy, almost all wanted pharmacogenomic testing and were willing-to-pay for it, waiting several weeks for results. Although patients had a strong desire to be involved in decision-making on pharmacogenomic testing, a considerable proportion lacked the necessary knowledge to make informed choices.
AB - BACKGROUND: Pharmacogenomics is gaining increasing importance in the therapeutics of cancer; yet, there is little knowledge of cancer patients' attitudes toward the use of pharmacogenomic testing in clinical practice. We carried out this study to explore cancer patients' acceptance, understanding, and willingness-to-pay for pharmacogenomic testing. MATERIALS AND METHODS: A broad cross-section of gastrointestinal, lung, breast, and other cancer patients were interviewed in terms of their acceptance of pharmacogenomic testing using hypothetical time, efficacy, and toxicity trade-off and willingness-to-pay scenarios. RESULTS: Among the 96% of 123 adjuvant patients accepting chemotherapy under optimal conditions, 99% wanted pharmacogenomic testing that could identify a subset of patients benefiting from chemotherapy, accepting median incurred costs of $2000 (range $0-25000) and turnaround time for test results of 16 days (range 0-90 days). Among the 97% of 121 metastatic patients accepting chemotherapy, 97.4% wanted pharmacogenomic testing that could detect the risk of severe toxicity, accepting median incurred costs of $1000 (range $0-10000) and turnaround time for results of 14 days (range 1-90 days). The majority of patients wanted to be involved in decision-making on pharmacogenomic testing; however, one in five patients lacked a basic understanding of pharmacogenomic testing. CONCLUSION: Among cancer patients willing to undergo chemotherapy, almost all wanted pharmacogenomic testing and were willing-to-pay for it, waiting several weeks for results. Although patients had a strong desire to be involved in decision-making on pharmacogenomic testing, a considerable proportion lacked the necessary knowledge to make informed choices.
KW - patient preference
KW - personalised medicine
KW - pharmacogenomics
UR - http://www.scopus.com/inward/record.url?scp=84902175252&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84902175252&partnerID=8YFLogxK
U2 - 10.1097/FPC.0000000000000061
DO - 10.1097/FPC.0000000000000061
M3 - Article
C2 - 24911662
AN - SCOPUS:84902175252
SN - 1744-6872
VL - 24
SP - 348
EP - 355
JO - Pharmacogenetics and Genomics
JF - Pharmacogenetics and Genomics
IS - 7
ER -